Cefepime Induced Neurotoxicity in Patients With or Without a History of Seizures: A Retrospective Matched Cohort Study

Abstract

Background: Cefepime is used for the treatment of nosocomial infections and serves as a carbapenem-sparing agent for treating AmpC inducible bacteria. Cefepime induced neurotoxicity (CIN) is a well-documented adverse effect, although data describing the risk of CIN in patients with a history of seizures (HOS) remains limited. Objectives: The primary and secondary objectives were to compare the rates of CIN in patients with and without HOS and identify risk factors associated with CIN, respectively. Methods: This was a retrospective matched cohort study of patients admitted to University Hospital from January 2019 to December 2022 that were initiated on cefepime with and without a baseline HOS. Patients were matched at a rate of 1:1 by age (+/− 5 years), sex, and month of admission (+/− 1 month). Results: A total of 150 patients were included, 75 in each group. There was no statistically significant difference in CIN between the two groups (9 vs 7, P = 0.7923). The only risk factors associated with CIN were age >65 (OR, 5.8 [95% CI, 1.194-27.996]), acute kidney injury (AKI) during cefepime administration (OR, 13.8 [95% CI, 2.528-75.206]), and an intensive care unit (ICU) stay (OR, 8.6 [95% CI, 1.735-42.624]). Conclusion: There was no increased risk of CIN observed in patients with HOS. Patients age >65, AKI while receiving cefepime and those admitted to the ICU were 5.8, 13.8, and 8.6 times more likely to experience CIN. These results suggest that it may be safe to administer cefepime to patients with HOS in the appropriate clinical setting.

Keywords

cefepime neurotoxicity beta-lactams seizures epilepsy

Get full access to this article

View all access options for this article.

References

Wong-Beringer

. Treating serious infections: focus on cefepime. Pharmacotherapy. 2004;24(12 Pt 2):216S-223S.

Tamma

Aitken

Bonomo

Mathers

van Duin

Clancy

. Infectious Diseases Society of America Antimicrobial-Resistant Treatment Guidance: Gram-Negative Bacterial Infections. Infectious Diseases Society of America 2023. Available at https://www.idsociety.org/practice-guideline/amr-guidance/Accessed 10 October, 2023.

Tamma

Doi

Bonomo

Johnson

Simner

. A primer on AmpC β-Lactamases: necessary knowledge for an increasingly Multidrug-resistant World. Clin Infect Dis. 2019;69(8):1446-1455.

Livermore

Mushtaq

Warner

Turner

Woodford

. Potential of high-dose cefepime/tazobactam against multiresistant Gram-negative pathogens. J Antimicrob Chemother. 2018;73(1):126-133. doi:10.1093/jac/dkx360.

Wong

et al. Piperacillin/tazobactam versus cefepime or carbapenems for cefoxitin-non-susceptible Enterobacter cloacae, Klebsiella aerogenes, Citrobacter freundii, Serratia marcescens and Morganella morganii bacteraemia in immunocompromised patients. J Antimicrob Chemother. 2023;78(4):1009-1014. doi:10.1093/jac/dkad037.

Luther

Timbrook

Caffrey

Dosa

Lodise

LaPlante

. Vancomycin Plus Piperacillin-Tazobactam and acute kidney injury in adults: a systematic review and meta-analysis. Crit Care Med. 2018;46(1):12-20. doi:10.1097/CCM.0000000000002769.

Roger

Louart

. Beta-lactams toxicity in the intensive care unit: an Underestimated Collateral Damage? Microorganisms. 2021;9(7):1505.

Deshayes

Coquerel

Verdon

. Neurological adverse effects attributable to β-Lactam Antibiotics: a literature review. Drug Saf. 2017;40(12):1171-1198. doi: 10.1007/s40264-017-0578-2.

Maan

Keitoku

Kimura

et al. Cefepime-induced neurotoxicity: systematic review. J Antimicrob Chemother. 2022;77(11):2908-2921. doi:10.1093/jac/dkac271.

10.

Payne

Gagnon

Riker

et al. Cefepime-induced neurotoxicity: a systematic review. Crit Care. 2017;21(1):276. doi:10.1186/s13054-017-1856-1.

11.

Lau

Marriott

Gould

Andresen

Reuter

Penm

. A retrospective study to determine the cefepime-induced neurotoxicity threshold in hospitalized patients. J Antimicrob Chemother. 2020;75(3):718-725. doi:10.1093/jac/dkz476.

12.

Boschung-Pasquier

Atkinson

Kastner

et al. Cefepime neurotoxicity: thresholds and risk factors. A retrospective cohort study. Clin Microbiol Infect. 2020;26(3):333-339. doi:10.1016/j.cmi.2019.06.028.

13.

Vercheval

Sadzot

Maes

Denooz

Damas

Frippiat

. Continuous infusion of cefepime and neurotoxicity: a retrospective cohort study. Clin Microbiol Infect. 2020;9(20):30386-30394. doi:10.1016/j.cmi.2020.07.003.

14.

Huwyler

Lenggenhager

Abbas

et al. Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study. Clin Microbiol Infect. 2017;23(7):454-459. doi:10.1016/j.cmi.2017.01.005.

15.

Fiest

Sauro

Wiebe

et al. Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies. Neurology. 2017;88(3):296-303. doi:10.1212/WNL.0000000000003509.

16.

Qian

Casey

Wright

et al. Cefepime vs piperacillin-tazobactam in adults hospitalized with acute infection: the ACORN randomized clinical trial. JAMA. 2023;330(16):1557-1567. doi:10.1001/jama.2023.20583.

17.

World

Health

Organization (WHO)-Uppsala Monitoring Centre. The use of the WHO-UMC system for standardized case causality assessment. Available from: https://www.who-umc.org/Graphics/24734.pdf. Accessed January 22, 2024.

18.

Brown

Masselink

Lalla

. Functional range of creatinine clearance for renal drug dosing: a practical solution to the controversy of which weight to use in the Cockcroft-Gault equation. Ann Pharmacother. 2013;47(7-8):1039-1044. doi: 10.1345/aph.1S176.

19.

Inker

Eneanya

Coresh

et al. New creatinine- and Cystatin C-based equations to estimate GFR without Race. N Engl J Med. 2021;385(19):1737-1749. doi:10.1056/NEJMoa2102953

20.

Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group . KDIGO clinical practice guideline for acute kidney injury. Kidney inter., Suppl 2012;2:1–138.

21.

Cefepime . Lexi-Drugs. Hudson, OH: Lexicomp, 2015. http://online.lexi.com/. Updated September 19, 2023. Accessed September 26, 2023.

22.

Al-Hasan

Eckel-Passow

Baddour

. Cefepime effectiveness in Gram-negative bloodstream infections. J Antimicrob Chemother. 2011;66(5):1156-1160. doi: 10.1093/jac/dkr061.

23.

Fratoni

Nicolau

Kuti

. A guide to therapeutic drug monitoring of β-lactam antibiotics. Pharmacotherapy. 2021;41(2):220-233. doi: 10.1002/phar.2505.

24.

Bausch

Araschmid

Hardmeier

Osthoff

. Cefepime-induced neurotoxicity in the setting of acute kidney Injury: a case series and discussion of preventive measures. Cureus. 2022;14(6):e26392.

25.

Lindsay

Gruner

Brackett

. Cefepime-induced neurotoxicity despite dose adjustment for renal disease: a brief report and review of the literature. J Pediatric Infect Dis Soc. 2017;6(2):199-201. doi:10.1093/jpids/piw022.

26.

Triplett

Lawn

Chan

Dunne

. Cephalosporin-related neurotoxicity: Metabolic encephalopathy or non-convulsive status epilepticus? J Clin Neurosci. 2019;67:163-166. doi:10.1016/j.jocn.2019.05.035.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.01 MB